JP2004168768A5 - - Google Patents

Download PDF

Info

Publication number
JP2004168768A5
JP2004168768A5 JP2003369875A JP2003369875A JP2004168768A5 JP 2004168768 A5 JP2004168768 A5 JP 2004168768A5 JP 2003369875 A JP2003369875 A JP 2003369875A JP 2003369875 A JP2003369875 A JP 2003369875A JP 2004168768 A5 JP2004168768 A5 JP 2004168768A5
Authority
JP
Japan
Prior art keywords
enoyl
pyrazol
fluorophenyl
prop
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003369875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004168768A (ja
JP4145230B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2003369875A priority Critical patent/JP4145230B2/ja
Priority claimed from JP2003369875A external-priority patent/JP4145230B2/ja
Publication of JP2004168768A publication Critical patent/JP2004168768A/ja
Publication of JP2004168768A5 publication Critical patent/JP2004168768A5/ja
Application granted granted Critical
Publication of JP4145230B2 publication Critical patent/JP4145230B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003369875A 2002-11-01 2003-10-30 神経障害の予防・治療剤 Expired - Fee Related JP4145230B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003369875A JP4145230B2 (ja) 2002-11-01 2003-10-30 神経障害の予防・治療剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002320153 2002-11-01
JP2003369875A JP4145230B2 (ja) 2002-11-01 2003-10-30 神経障害の予防・治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008128851A Division JP2008231115A (ja) 2002-11-01 2008-05-15 神経障害の予防・治療剤

Publications (3)

Publication Number Publication Date
JP2004168768A JP2004168768A (ja) 2004-06-17
JP2004168768A5 true JP2004168768A5 (enExample) 2008-07-03
JP4145230B2 JP4145230B2 (ja) 2008-09-03

Family

ID=32715932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003369875A Expired - Fee Related JP4145230B2 (ja) 2002-11-01 2003-10-30 神経障害の予防・治療剤

Country Status (1)

Country Link
JP (1) JP4145230B2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060135854A (ko) * 2004-04-01 2006-12-29 아벤티스 파마슈티칼스 인크. Ppar 델타 조절물질로서의 1,3,4-옥사디아졸-2-온
WO2005097763A2 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as ppar delta
BRPI0512623A (pt) * 2004-06-25 2008-03-25 Janssen Phamaceutica N V sal quaternário antagonista de ccr2
EP2039779A1 (en) * 2006-07-19 2009-03-25 Takeda Pharmaceutical Company Limited Screening method
EP1939180A1 (en) * 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
TWI574957B (zh) 2011-07-29 2017-03-21 佳佑製藥治療公司 含有醯肼的核運輸調控子及其用途
WO2013019561A1 (en) * 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
RS58058B1 (sr) 2012-05-09 2019-02-28 Biogen Ma Inc Modulatori nukleusnog transporta i njihove upotrebe
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
DK3010892T3 (en) 2013-06-21 2019-04-15 Karyopharm Therapeutics Inc 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND APPLICATIONS THEREOF
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
GB201901559D0 (en) * 2019-02-05 2019-03-27 Syngenta Crop Protection Ag Herbicidal compositions

Similar Documents

Publication Publication Date Title
JP2004168768A5 (enExample)
JP2008506632A5 (enExample)
NO20050542L (no) Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin
JP2005518413A5 (enExample)
JP2004538039A5 (enExample)
JP2010507641A5 (enExample)
AU2003248259A1 (en) Novel azetidine derivative or salt thereof
DK1663989T3 (da) Krystallisk form af bis(E)-7-[4(4-fluorphenyl)-6-isopropyl-2-methyl(methylsulfonyl)aminopyrimidin-5-yl(3R,5S))-3-5-dihydroxyhept-6-ensyrecalciumsalt
HRP20090229T1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate
JP2006512924A5 (enExample)
JP2006526031A5 (enExample)
JP2005526081A5 (ja) 代謝型グルタメート受容体−5の二アリール置換テトラゾールモジュレータ
JP2007508034A5 (enExample)
CY1112796T1 (el) Μεθανοσουλφονικος 3-[(2{[4-(εξυλοξυκαρβοονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]μεθυλ}-1-μεθυλ-1h-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικος αιθυλεστερας
AU2003227360A1 (en) Novel amide derivatives or salts thereof
NO20041082L (no) Fremgangsmater for fremstilling av kalsiumsaltformer av statiner
WO2005051322A3 (en) Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
ATE464297T1 (de) Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz
JP2004149545A5 (enExample)
JP2007520206A5 (enExample)
PL370850A1 (pl) Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
JP2007119504A5 (enExample)
NO20054169D0 (no) 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.
JP2004123690A5 (enExample)
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess